Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib datanews2022-05-12T01:55:41+00:00May 12th, 2022|FierceBiotech|
Caribou ready to uncork the chardonnay thanks to first-in-human CAR-T resultsnews2022-05-11T19:19:48+00:00May 11th, 2022|FierceBiotech|
Former Immunomedics CFO Usama Malik indicted for insider trading, pledging to dispute ‘false and speculative narrative’ at trialnews2022-05-11T17:51:04+00:00May 11th, 2022|FierceBiotech|
Welcome to new (Bio) Haven: CEO hopes to strike gold twice with remaining R&D crew after Pfizer dealnews2022-05-11T14:45:42+00:00May 11th, 2022|FierceBiotech|
Novo Nordisk, Flagship’s forward-thinking partnership aims to treat cardiometabolic, rare diseasesnews2022-05-11T14:37:58+00:00May 11th, 2022|FierceBiotech|
Bioasis, Neuramedy to cross blood-brain barrier together in $72M licensing dealnews2022-05-11T14:23:55+00:00May 11th, 2022|FierceBiotech|
After failed SPAC and phase 3 fumble, Amicus gene therapy hits another delay to approvalnews2022-05-11T13:43:20+00:00May 11th, 2022|FierceBiotech|
After phase 3 fumble and failed SPAC, Amicus’ Pompe disease drug hits another delay to approvalnews2022-05-11T13:43:20+00:00May 11th, 2022|FierceBiotech|
Inovio CEO departs, leaving Jacqueline Shea in charge of ‘particularly challenging period’ in the DNA vaccine biotech’s historynews2022-05-11T13:30:24+00:00May 11th, 2022|FierceBiotech|
Inflammation space swells further as Nuvig unveils $47M to transform autoimmune therapiesnews2022-05-11T11:47:10+00:00May 11th, 2022|FierceBiotech|
